Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,504 active trials253 approved drugs3,568 evidence items
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,622 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04974008 | Osteosarcoma Maintenance Therapy With OST31-164(OST-164-01) | active not recruiting | Phase 2 | 39 | Emerald Clinical Inc.INDUSTRY | 1 | Jan 22, 2025 | clinicaltrials |
| NCT05228197 | Imperial Prostate 6 - Cancer Histology Artificial Intelligence Reliability Study.(IP6-CHAIROS) | active not recruiting | — | 750 | Imperial College LondonOTHER | 1 | Jan 22, 2025 |
| clinicaltrials |
| NCT05932836 | An Organoid-on-chips Technique Based on Biopsy Samples and Its Efficacy in Predicting the Response to HAI in HCC | active not recruiting | — | 165 | Xiangya Hospital of Central South UniversityOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT02149030 | Effectiveness of Cervical Screening in HPV Vaccinated Women(HPV-004) | active not recruiting | N/A | 6,958 | Tampere UniversityOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT03881605 | MRI Screening Versus SYMptom-directed Surveillance for Brain Metastases Among Patients with Triple Negative or HER2+ MBC(SYMPToM) | active not recruiting | N/A | 50 | Sunnybrook Health Sciences CentreOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06782698 | Home-Based Exercise Program During Neoadjuvant Treatment to Improve Fatigue and Quality of Life in Early HER2-Positive and Triple-Negative Breast Cancer Patients(HoPEx-Breast) | active not recruiting | N/A | 50 | Centro Hospitalar Universitário de Santo AntónioOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT02811224 | Ovarian Cancer Hemoscope Trial | active not recruiting | — | 50 | Scripps Translational Science InstituteOTHER | 0 | Jan 16, 2025 | clinicaltrials |
| NCT03769506 | ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy | active not recruiting | Phase 3 | 135 | Rakuten Medical, Inc.INDUSTRY | 4 | Jan 16, 2025 | clinicaltrials |
| NCT04215146 | A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study | active not recruiting | Phase 2 | 48 | Oncolytics BiotechINDUSTRY | 1 | Jan 16, 2025 | clinicaltrials |
| NCT04782687 | Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 2 | 73 | US Oncology ResearchINDUSTRY | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06480734 | Pneumonitis in Older Lung Cancer Patients After Radiotherapy(POLCAR) | active not recruiting | N/A | 62 | University Hospital Schleswig-HolsteinOTHER | 2 | Jan 16, 2025 | clinicaltrials |
| NCT02299999 | SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer(SAFIR02_Breast) | active not recruiting | Phase 2 | 1,460 | UNICANCEROTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06776055 | Long-term Follow-up of Bivalent Human Papillomavirus (HPV) Vaccine Study in Women | active not recruiting | — | 5,372 | Shanghai Zerun Biotechnology Co.,LtdINDUSTRY | 1 | Jan 15, 2025 | clinicaltrials |
| NCT03546361 | CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer | active not recruiting | Phase 1 | 24 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT03709680 | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | active not recruiting | Phase 2 | 128 | PfizerINDUSTRY | 14 | Jan 14, 2025 | clinicaltrials |
| NCT05263583 | Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma | active not recruiting | Phase 2 | 14 | Cothera Bioscience, IncINDUSTRY | 2 | Jan 14, 2025 | clinicaltrials |
| NCT03840421 | GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 468 | Sun Yat-sen UniversityOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT04009967 | Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning(PICT-01) | active not recruiting | Phase 2 | 30 | CHU de Quebec-Universite LavalOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT05885464 | A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) | active not recruiting | Phase 1 / Phase 2 | 5 | Beam Therapeutics Inc.INDUSTRY | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06770699 | Tertiary Lymphoid Structures in Nasopharyngeal Carcinoma | active not recruiting | — | 260 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06771596 | Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the Cervix(CC11) | active not recruiting | Phase 2 | 43 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT04440735 | A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 125 | Kahr MedicalINDUSTRY | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06765395 | Explore Association Models Between Environmental Hormones andBreast Cancer | active not recruiting | — | 687 | Pei-Hung LiaoOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06766019 | Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer | active not recruiting | Phase 2 | 47 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT04404595 | Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers | active not recruiting | Phase 1 / Phase 2 | 110 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 2 | Jan 8, 2025 | clinicaltrials |
| NCT04786028 | A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM | active not recruiting | Phase 2 | 72 | Canadian Myeloma Research GroupOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT05479578 | Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer | active not recruiting | Phase 1 | 7 | Rashmi Verma, MDOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT05688280 | Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS(INJECTABL-1) | active not recruiting | Phase 1 / Phase 2 | 42 | Immunophotonics, Inc.INDUSTRY | 5 | Jan 8, 2025 | clinicaltrials |
| NCT06764589 | Liquid Micro-biopsy: a Novel Approach to Study Tumor Microenvironment From the Peripheral Blood | active not recruiting | — | 90 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT03368963 | TAS102 in Combination With NAL-IRI in Advanced GI Cancers | active not recruiting | Phase 1 / Phase 2 | 64 | Emory UniversityOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT05838131 | Study of CT071 Injection in RRMM or PPCL | active not recruiting | Early Phase 1 | 20 | Shanghai Changzheng HospitalOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06760936 | Pixantrone as Bridging Therapy to Allogenic Transplant or CAR-T Cell Therapy in DLBCL Patients(PIXBRIDGE) | active not recruiting | — | 15 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06761599 | Frequency of Pulmonary Toxicity in Patients Treated for Hodgkin Lymphoma | active not recruiting | — | 214 | Superior UniversityOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06762158 | NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC | active not recruiting | N/A | 50 | RenJi HospitalOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT04476199 | Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT | active not recruiting | Phase 2 | 100 | Gruppo Italiano Trapianto di Midollo OsseoOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT05377736 | Thyroid Nodule Gene Sequencing in a Danish Population | active not recruiting | N/A | 30 | Aarhus University HospitalOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT04295317 | PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery | active not recruiting | Phase 2 | 65 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 3, 2025 | clinicaltrials |
| NCT05302648 | To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM | active not recruiting | Early Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 3, 2025 | clinicaltrials |
| NCT05522231 | Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2) | active not recruiting | Phase 2 / Phase 3 | 265 | HutchmedINDUSTRY | 1 | Jan 3, 2025 | clinicaltrials |
| NCT05636943 | Couples' QOL in Metastatic Breast Cancer(C-QOL) | active not recruiting | N/A | 110 | Fox Chase Cancer CenterOTHER | 1 | Jan 3, 2025 | clinicaltrials |
| NCT04160546 | Study to Evaluate the Reinduction and Second Stop of TKI with Ponatinib in CML in Molecular Response (ResToP)(ResToP) | active not recruiting | Phase 2 | 80 | Fundacion CRIS de Investigación para Vencer el CáncerOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT04691804 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 3 | 496 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 13 | Dec 31, 2024 | clinicaltrials |
| NCT06754293 | Evaluating the Efficacy of Structured Exercise Interventions in Alleviating Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors: a Pilot Study Protocol(RE-MS) | active not recruiting | N/A | 24 | Fudan UniversityOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT04174391 | Lifestyles and Breast Cancer(LifeBreast) | active not recruiting | N/A | 766 | University of NavarraOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT04593615 | Indocyanine Green Tracer Using in Laparoscopic Radical Gastrectomy for Locally Advanced Gastric Cancer(CLASS-11) | active not recruiting | N/A | 1,070 | Fujian Medical UniversityOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT04827953 | Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer(NUMANTIA) | active not recruiting | Phase 1 / Phase 2 | 28 | Nelum CorpINDUSTRY | 1 | Dec 30, 2024 | clinicaltrials |
| NCT05712902 | Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6) | active not recruiting | Phase 2 | 104 | Dizal PharmaceuticalsINDUSTRY | 1 | Dec 30, 2024 | clinicaltrials |
| NCT05869227 | Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 166 | XIANG YANQUNOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06414577 | Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy | active not recruiting | Phase 2 | 38 | XIANG YANQUNOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT02112214 | Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General Population(HELPER) | active not recruiting | Phase 3 | 5,224 | National Cancer Center, KoreaOTHER_GOV | 1 | Dec 27, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Jan 22, 2025source: clinicaltrials